You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.